Lupin rose 0.36% to Rs 765 at 15:09 IST on BSE after securing US drug regulator's approval for a generic drug indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
The announcement was made during trading hours today, 19 March 2018.
Meanwhile, the S&P BSE Sensex was down 290.66 points or 0.88% at 32,885.34.
Read more: http://www.business-standard.com/article/news-cm/lupin-inches-up-after-fda-nod-for-generic-drug-118031900492_1.html